Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Investing in late-stage companies: Forbion closes Growth Fund at €185m

Forbion has closed its new Growth Opportunities Fund at €185m, but it is hoping to raise a further €65m before the fund is completed this year. This fund will invest in promising late-stage companies, an underserved market, with the support of its expert Advisory Group.

Close
Close
Close

Go Top